Dialysis industry news

Stories from the dialysis comunity across the globe.



JEFF EDELSTEIN: For Hamilton kidney dialysis patient, a living room solution - The Trentonian PDF Print

JEFF EDELSTEIN: For Hamilton kidney dialysis patient, a living room solution
The Trentonian
And while a generation or two ago Greenberg's condition would have been a death sentence, these days Greenberg is … well, he's living his life almost exactly as he was before thanks to some nifty technology not all dialysis patients are aware of.

...

 
Should We Target Magnesium Levels in Patients With CKD? - Medscape PDF Print

In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.

Medscape uses cookies to customize the site based on the information we collect at registration. The cookies contain no personally identifiable information and have no effect once you leave the Medscape site.

...

 
Fresenius Medical Care AG Co. Downgraded to Hold at Societe Generale (FMS) - Dakota Financial News PDF Print

Societe Generale cut shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a buy rating to a hold rating in a research report sent to investors on Thursday, TheFlyOnTheWall.com reports.

Several other research firms have also recently issued reports on FMS. Commerzbank AG lowered shares of Fresenius Medical Care AG & Co. to a hold rating in a report on Friday, May 29th. RBC Capital boosted their price objective on shares of Fresenius Medical Care AG & Co. from $35.00 to $40.00 and gave the stock a sector perform rating in a research note on Friday, July 31st. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $41.10.

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) traded up 0.91% during midday trading on Thursday, reaching $41.15. 78,366 shares of the company traded hands. The company has a 50 day moving average price of $42.26 and a 200 day moving average price of $41.45. The company has a market capitalization of $25.07 billion and a PE ratio of 23.66. Fresenius Medical Care AG & Co. has a 1-year low of $32.40 and a 1-year high of $44.34.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by $0.02. The business had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.13 billion. Fresenius Medical Care AG & Co.’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period last year, the business posted $0.42 earnings per share. On average, analysts expect that Fresenius Medical Care AG & Co. will post $1.75 earnings per share for the current year.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.image

The Fly On The Wall

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

...

 
Recent Release: Global Haemorrhagic Fever with Renal Syndrome Vaccine Industry ... - Medgadget.com (blog) PDF Print
Mrrbiz-Logo256

The Report Global Haemorrhagic Fever with Renal Syndrome Vaccine Industry 2015 Market Research Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz

The Global Haemorrhagic Fever with Renal Syndrome Vaccine Industry Report 2015 is a professional and in-depth study on the current state of the Haemorrhagic Fever with Renal Syndrome Vaccine industry.

View Full Report at http://www.marketresearchreports.biz/analysis/271580
The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Haemorrhagic Fever with Renal Syndrome Vaccine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand figures, cost price and production value gross margins.

The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Haemorrhagic Fever with Renal Syndrome Vaccine industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered.

Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/271580

With 132 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table of Contents

Chapter One Haemorrhagic Fever with Renal Syndrome Vaccine Industry Overview
1.1 Haemorrhagic Fever with Renal Syndrome Vaccine Definition
1.1.1 Haemorrhagic Fever with Renal Syndrome Vaccine Definition
1.1.2 Product Specifications
1.2 Haemorrhagic Fever with Renal Syndrome Vaccine Classification
1.2.1 2014 Global Haemorrhagic Fever with Renal Syndrome Vaccine Sales Market Share by Product Type
1.3 Haemorrhagic Fever with Renal Syndrome Vaccine Application
1.3.1 2014 Global Haemorrhagic Fever with Renal Syndrome Vaccine Sales Market Share by Application
1.4 Haemorrhagic Fever with Renal Syndrome Vaccine Industry Chain Structure
1.5 Haemorrhagic Fever with Renal Syndrome Vaccine Industry Regional Overview
1.6 Haemorrhagic Fever with Renal Syndrome Vaccine Industry Policy Analysis
1.7 Haemorrhagic Fever with Renal Syndrome Vaccine Industry News Analysis

Chapter Two Haemorrhagic Fever with Renal Syndrome Vaccine Manufacturing Cost Structure Analysis
2.1 Raw Material Supplier and Price Analysis
2.2 Equipment Suppliers and Price Analysis
2.3 Labor Cost Analysis
2.4 Other Cost Analysis
2.5 Manufacturing Cost Structure Analysis
2.6 Haemorrhagic Fever with Renal Syndrome Vaccine Manufacturing Process Analysis

About Us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Read our latest articles at http://www.marketresearchreports.biz/articles
Browse blogs at http://medicalechnologyandinnovation.blogspot.com/

Contact  Us

Office: State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

...

 
Rockwell Medical, Inc. (RMTI) Files Form 4 Insider Buying : Robert L Chioini ... - Insider Trading Report PDF Print

Rockwell Medical, Inc. (RMTI): Robert L Chioini , CEO of Rockwell Medical, Inc. purchased 4,910 shares on Aug 14, 2015. The Insider buying transaction was disclosed on Aug 14, 2015 to the Securities and Exchange Commission. The shares were purchased at $11.96 per share for a total value of $58,723.60.

Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0% in the total insider ownership. Institutional Investors own 34.4% of Company shares. During last 3 month period, 25.61% of total institutional ownership has changed in the company shares. Rockwell Medical, Inc. (NASDAQ:RMTI): The stock price is expected to reach $ 16.6 in the short term. The number of analysts agreeing with this consensus is 5. The higher estimate for the short term price target is at $26 while the lower estimate is at $4. The standard deviation of the price stands at $7.99. The company shares have rallied 25.52% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $18.90 and the one year low was seen on Dec 15, 2014. The 50-Day Moving Average price is $15.83 and the 200 Day Moving Average price is recorded at $12.05. Rockwell Medical, Inc. (NASDAQ:RMTI) : On Monday heightened volatility was witnessed in Rockwell Medical, Inc. (NASDAQ:RMTI) which led to swings in the share price. The shares opened for trading at $14.15 and hit $14.53 on the upside , eventually ending the session at $14.09, with a gain of 0.86% or 0.12 points. The heightened volatility saw the trading volume jump to 533,528 shares. The 52-week high of the share price is $18.8999 and the company has a market cap of $708 million. The 52-week low of the share price is at $8.095 . Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...

 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 18 of 4210
Share |
Copyright © 2017 Global Dialysis. All Rights Reserved.